Lyra Therapeutics operates with a lean clinical-stage biotechnology workforce numbering approximately 16 total employees, primarily concentrated in North America. The organization's headcount distribution supports its specialized research, regulatory compliance, and development pipelines dedicated to novel-delivery drug therapies for ear, nose, and throat diseases, shifting in response to strategic clinical milestones and operational restructuring phases.